Merck KGaA (ETR: MRK)
Germany
· Delayed Price · Currency is EUR
158.80
-1.75 (-1.09%)
Sep 30, 2024, 2:14 PM CET
Merck KGaA Revenue
Merck KGaA had revenue of 5.35B EUR in the quarter ending June 30, 2024, with 0.94% growth. This brings the company's revenue in the last twelve months to 20.87B, down -5.40% year-over-year. In the year 2023, Merck KGaA had annual revenue of 20.99B, down -5.57%.
Revenue (ttm)
20.87B
Revenue Growth
-5.40%
P/S Ratio
3.34
Revenue / Employee
335.66K
Employees
62,176
Market Cap
69.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.99B | -1.24B | -5.57% |
Dec 31, 2022 | 22.23B | 2.55B | 12.93% |
Dec 31, 2021 | 19.69B | 2.15B | 12.28% |
Dec 31, 2020 | 17.53B | 1.38B | 8.56% |
Dec 31, 2019 | 16.15B | 1.32B | 8.87% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMerck KGaA News
- 20 days ago - MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing - Financial Post
- 25 days ago - Germany’s DAX 40 has a new female CEO: Daimler Truck appoints Karin Radstrom as next head in rare move - Fortune
- 27 days ago - MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing - Financial Post
- 4 weeks ago - Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG) - Business Wire
- 2 months ago - Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Merck KGaA: The Drop Makes The Upside All The Sweeter - Seeking Alpha
- 3 months ago - Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer - Business Wire
- 4 months ago - Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024 - Business Wire